Scientific platforms


Synthon started the development of biopharmaceutical medicines based on therapeutic proteins in 2007.

The biopharmaceutical franchise focuses on biosimilar antibody development and new biological entities. This highly innovative business covers a wide spectrum of technologies: from complex small molecule chemistries, to cell line development and fermentation, protein purification, analytics, formulation and development of highly innovative biologics.

Our principal technology platforms comprise antibody-drug conjugate (ADC) technology, comprising a unique linker-drug platform to generate novel ADC candidates, and monoclonal antibody technology.